Semaglutide: FDA-Approved Weight Management

⚠️ Medical Disclaimer: This article is for educational purposes only. It is not medical advice. Semaglutide is a prescription medication. Always consult your doctor before starting any treatment.

---

Introduction

Semaglutide has revolutionized the treatment of type 2 diabetes and chronic weight management, receiving FDA approval for both indications. Originally developed by Novo Nordisk as a diabetes medication (Ozempic), its dramatic weight loss effects led to a separate approval under the brand name Wegovy.

As of 2026, semaglutide remains the most prescribed GLP-1 receptor agonist globally, with demand consistently outpacing supply.

How Semaglutide Works

Semaglutide mimics a natural hormone called GLP-1 (glucagon-like peptide-1) that your body produces after eating. It works through several mechanisms:

Appetite Suppression

• Activates GLP-1 receptors in the brain's hypothalamus
• Reduces hunger signals and increases feelings of fullness
• Most patients report significantly reduced food cravings

Blood Sugar Regulation

• Stimulates insulin secretion when blood sugar is high
• Suppresses glucagon (which raises blood sugar)
• Slows stomach emptying, reducing post-meal glucose spikes

Metabolic Effects

• May improve insulin sensitivity in peripheral tissues
• Reduces liver fat accumulation
• Emerging evidence of cardiovascular protective effects

Clinical Trial Results

STEP Trials (Weight Management)

The landmark STEP (Semaglutide Treatment Effect in People with Obesity) trials showed remarkable results:

• STEP 1: Patients lost an average of 14.9% body weight over 68 weeks vs 2.4% with placebo
• STEP 2 (diabetic patients): 9.6% weight loss vs 3.4%
• STEP 3 (with behavioral therapy): 16% weight loss vs 5.7%
• STEP 5 (long-term): Weight loss maintained through 104 weeks of treatment

SELECT Trial (Cardiovascular)

Published in 2023, the SELECT trial demonstrated:
- 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death)
- Benefits observed regardless of diabetes status
- Led to an expanded FDA indication for cardiovascular risk reduction

Dosage and Administration

Semaglutide for weight management (Wegovy) follows a gradual dose escalation:

The slow titration helps minimize gastrointestinal side effects.

Common Side Effects

The most frequently reported side effects are gastrointestinal:

• Nausea (44% of patients in trials, usually temporary)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Abdominal pain (20%)

These effects typically diminish after 4-8 weeks as the body adjusts. The gradual dose escalation helps reduce their severity.

Serious Risks

Less common but important risks include:

• Pancreatitis — inflammation of the pancreas (rare but serious)
• Gallbladder problems — rapid weight loss increases gallstone risk
• Thyroid tumors — seen in rodent studies; relevance to humans unknown. Contraindicated in patients with personal/family history of medullary thyroid carcinoma
• Hypoglycemia — primarily when combined with other diabetes medications

The Supply Problem

Since its approval, semaglutide has faced persistent shortages:

• Novo Nordisk invested over billion in manufacturing expansion
• Compounding pharmacies filled the gap but faced FDA scrutiny
• The shortage has fueled a gray market of unregulated alternatives
• As of early 2026, supply is improving but not fully resolved

Oral Semaglutide

Novo Nordisk has also developed an oral form:
- Rybelsus — oral tablet for type 2 diabetes (approved 2019)
- Oral Wegovy — higher-dose oral formulation for weight management (FDA approval expected 2025-2026)
- Oral versions use an absorption enhancer (SNAC) to protect the peptide from stomach acid

See our detailed article: Oral Wegovy vs Injectable Semaglutide

Cost and Access

• Wegovy list price: ~,350/month
• Insurance coverage: Improving but inconsistent. Many plans now cover it for BMI ≥30 or BMI ≥27 with comorbidities
• Compounded semaglutide: Significantly cheaper but quality varies. FDA has issued warnings about some compounding pharmacies
• International: Available in most countries but pricing and access vary

Key Takeaways

• Semaglutide is the most effective weight loss medication currently available
• Clinical trials show 15%+ average body weight loss
• The SELECT trial proved cardiovascular benefits
• GI side effects are common but usually temporary
• It requires ongoing use — weight tends to return after stopping
• Always obtain from legitimate pharmacies with a valid prescription

---

Last updated: January 2026